Introduction {#Sec1}
============

Osteoporosis is a chronic, systemic bone disorder that is characterized by low bone density, deterioration of bone tissue, loss of bone strength, and an increase in bone fracture risk \[[@CR1]\]. Treatment goals for osteoporosis encompass managing bone fracture risk by minimizing bone loss, increasing bone mineral density (BMD), and improving bone microarchitecture \[[@CR2], [@CR3]\]. This is accomplished primarily through therapy with anti-resorptive agents, including bisphosphonates, estrogen receptor agonists and antagonists, parathyroid hormone or its analogues, and monoclonal antibody therapy \[[@CR4]\].

Persistence and compliance are important for improving outcomes in patients with osteoporosis. Recent studies have shown that patients who are persistent and compliant have fewer total, vertebral, non-vertebral, and hip fractures \[[@CR5], [@CR6]\]. As persistence tends to decline over time, potentially leading to poorer outcomes, a long-term view of persistence is important in strategizing how to improve outcomes.

However, the majority of research to date has focused on persistence and compliance over a 1-year period, with limited information on long-term trends \[[@CR7]--[@CR11]\]. In these short-term studies, rates of persistence and compliance with oral bisphosphonates were generally poor (\<50%) \[[@CR12]--[@CR17]\]. These studies have generally found that patients are more persistent and compliant with injectable osteoporosis therapies---including denosumab, teriparatide, and zoledronic acid---compared with oral osteoporosis therapies---including oral bisphosphonates \[[@CR7], [@CR8], [@CR18]--[@CR20]\]. Similarly, Cheng et al. recently found that the rate of persistence among patients receiving denosumab was 68%, compared with 29--35% for bisphosphonates, 42% for raloxifene, and 59% for teriparatide during 1 year of follow-up \[[@CR7]\].

The primary objective of this study was to evaluate short- and long-term (i.e., 1- and 2-year) persistence and compliance with osteoporosis therapies among postmenopausal women with osteoporosis with commercial or Medicare supplemental insurance. In addition, this study compared short- and long-term persistence and compliance across different osteoporosis therapies and dosing regimens.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This was a retrospective, observational cohort study using administrative claims data from the *MarketScan*® databases, including the Commercial Claims and Encounters (Commercial), Medicare Supplemental and Coordination of Benefits (Medicare), and Early View databases. Patients were followed for at least 2 years after their index date---the date of their first new dispensing or medical claim for one of the osteoporosis therapies of interest (i.e., the index therapy), between January 1, 2012, and December 31, 2014. Persistence and compliance outcomes were measured at 12 and 24 months of follow-up.

Patients {#Sec4}
--------

Patients were included in this study if they were female; aged 50 years or older on their index date; had at least one pharmacy or medical claim for a Food and Drug Administration---approved osteoporosis therapy any time between January 1, 2012, and December 31, 2012; had at least 14 months of continuous enrollment with medical and pharmacy benefits before the index date (pre-index period); and had at least 24 months of continuous enrollment with medical and pharmacy benefits after the index date (post-index period).

Patients were excluded from this study if they had a diagnosis or evidence of the following during the pre-index period: treatment with the index therapy, Paget disease of the bone or other osteitis deformans and osteopathies, osteogenesis imperfecta, hypercalcemia, malignant cancer, human immunodeficiency virus infection, or preventive treatment for risk of breast cancer. Patients were also excluded if they had a cancer or metastasis diagnosis before a medical claim for denosumab or zoledronic acid in the post-index period (for patients receiving denosumab and zoledronic acid only), as these therapies may have been used in cancer rather than osteoporosis in these patients.

Treatment groups included injectable and oral therapies, as well as a range of dosing frequencies. The injectable therapies were denosumab subcutaneous (SC) injection every 6 months (Q6M), ibandronate intravenous (IV) injection every 3 months (Q3M), teriparatide daily SC, and zoledronic acid annual IV. The oral therapies were alendronate daily, alendronate weekly, ibandronate monthly, raloxifene daily, risedronate daily, risedronate weekly, and risedronate monthly.

Outcomes {#Sec5}
--------

Persistence was measured at 12 and 24 months after the index date and was defined as remaining on the index therapy during the respective follow-up period with no gap of \>60 days following the fill date plus the days' supply of the previous claim. Compliance was measured at 12 and 24 months after the index date and was defined using the medication possession ratio (MPR), or the total days supplied from all claims of the index therapy divided by the length of follow-up. Patients were considered compliant if the MPR was ≥0.80. Sensitivity analyses were also conducted for persistence outcomes using allowed gap periods of 30 or 90 days, instead of 60 days, over the course of 24 months.

Statistical analysis {#Sec6}
--------------------

Baseline patient characteristics and persistence and compliance outcomes were summarized using descriptive statistics. Multivariable logistic regression models were estimated to compare persistence and compliance across treatment/dosing regimens. Odds ratios (ORs) were calculated from logistic regression models comparing persistence and compliance with the Q6M injectable therapy (denosumab) with the other osteoporosis therapies of interest, adjusting for demographic and clinical characteristics at baseline (Table [3](#Tab3){ref-type="table"}). The models also incorporated adjusted propensity score weights.

Results {#Sec7}
=======

Patient disposition {#Sec8}
-------------------

A total of 564,186 adult patients were identified who had at least one pharmacy or medical claim for an osteoporosis therapy of interest between January 1, 2012, and December 31, 2012 (Fig. [1](#Fig1){ref-type="fig"}). Of those, a total of 43,543 patients met the eligibility criteria: 3599 (8.3%) received denosumab Q6M SC, 224 (0.5%) received alendronate daily, 19,486 (44.8%) received alendronate weekly, 5981 (13.7%) received ibandronate monthly, 165 (0.4%) received ibandronate IV Q3M, 3423 (7.9%) received raloxifene daily, 53 (0.1%) received risedronate daily, 2968 (6.8%) received risedronate weekly, 1986 (4.6%) received risedronate monthly, 1100 (2.5%) received teriparatide SC daily, and 4558 (10.5%) received zoledronic acid IV annually.Fig. 1Patient selection. ^a^Denosumab SC Q6M, alendronate QD oral, alendronate QW oral, ibandronate QM oral, ibandronate IV Q3M, risedronate QD oral, risedronate QW oral, risedronate QM oral, raloxifene, teriparatide SC QD, and zoledronic acid IV annual. *HIV* human immunodeficiency virus, *IV* intravenous, *QD* once daily, *QM* once monthly, *Q3M* once every 3 months, *Q6M* once every 6 months, *QW* once a week, *SC* subcutaneous

Demographic and clinical characteristics at baseline {#Sec9}
----------------------------------------------------

Overall, patients had a mean (standard deviation) age of 65 (10) years, 57.9% were below the age of 65 years, 51.4% were enrolled in a preferred provider organization health plan, and 84.1% were urban residents (Table [1](#Tab1){ref-type="table"}). During the baseline study period, 26.4 and 12.2% of patients had a diagnosis of osteoporosis and osteopenia, respectively. Among the study population, 7.8% of patients had experienced an osteoporosis-related fracture, while 36.7% were at a high risk for fracture, as defined by age 70 years or older or having had an osteoporotic fracture during the baseline period (Table [2](#Tab2){ref-type="table"}).Table 1Demographic and clinical characteristics at baselineCharacteristicAll *N* = 43,543Denosumab SC Q6M *n* = 3599Alendronate QD *n* = 224Alendronate QW *n* = 19,486Ibandronate QM *n* = 5981Ibandronate IV Q3M *n* = 165Raloxifene QD *n* = 3423Risedronate QD *n* = 53Risedronate QW *n* = 2968Risedronate QM *n* = 1986Teriparatide SC QD *n* = 1100Zoledronic acid IV annually *n* = 4558 Age, mean (SD)64.9 (10.4)68.4 (11.1)65.0 (10.5)64.9 (10.6)63.1 (9.8)68.2 (10.9)62.6 (9.1)68.2 (12.3)63.8 (10.1)63.2 (9.7)67.2 (10.8)66.7 (10.4)Age groups, *n* (%) 45--64 years25,212 (57.9)1577 (43.8)126 (56.3)11,221 (57.6)3903 (65.3)74 (44.8)2331 (68.1)23 (43.4)1884 (63.5)1324 (66.7)532 (48.4)2217 (48.6) ≥65 years18,331 (42.1)2022 (56.2)98 (43.8)8265 (42.4)2078 (34.7)91 (55.2)1092 (31.9)30 (56.6)1084 (36.5)662 (33.3)568 (51.6)2341 (51.4)Health insurance type, *n* (%) Comprehensive10,525 (24.2)1033 (28.7)58 (25.9)5008 (25.7)1377 (23.0)55 (33.3)684 (20.0)21 (39.6)472 (15.9)260 (13.1)304 (27.6)1253 (27.5) POS3495 (8.0)258 (7.2)21 (9.4)1530 (7.9)528 (8.8)16 (9.7)314 (9.2)3 (5.7)268 (9.0)189 (9.5)88 (8.0)280 (6.1) HMO4155 (9.5)262 (7.3)31 (13.8)2143 (11.0)463 (7.7)7 (4.2)244 (7.1)4 (7.5)263 (8.9)180 (9.1)75 (6.8)483 (10.6) PPO22,366 (51.4)1866 (51.8)99 (44.2)9333 (47.9)3206 (53.6)81 (49.1)1918 (56.0)19 (35.8)1719 (57.9)1229 (61.9)563 (51.2)2333 (51.2) Other2432 (5.6)135 (3.8)15 (6.7)1217 (6.2)338 (5.7)5 (3.0)217 (6.3)6 (11.3)177 (6.0)109 (5.5)60 (5.5)153 (3.4) Unknown570 (1.3)45 (1.3)0 (0.0)255 (1.3)69 (1.2)1 (0.6)46 (1.3)0 (0.0)69 (2.3)19 (1.0)10 (0.9)56 (1.2)Geographic region, *n* (%) Northeast8291 (19.0)643 (17.9)35 (15.6)3292 (16.9)1130 (18.9)54 (32.7)748 (21.9)8 (15.1)781 (26.3)638 (32.1)215 (19.5)747 (16.4) North Central12,419 (28.5)937 (26.0)71 (31.7)6172 (31.7)1410 (23.6)38 (23.0)922 (26.9)19 (35.8)620 (20.9)335 (16.9)312 (28.4)1583 (34.7) South17,036 (39.1)1589 (44.2)82 (36.6)7111 (36.5)2663 (44.5)46 (27.9)1317 (38.5)19 (35.8)1187 (40.0)793 (39.9)440 (40.0)1789 (39.2) West5431 (12.5)406 (11.3)36 (16.1)2760 (14.2)721 (12.1)27 (16.4)391 (11.4)7 (13.2)349 (11.8)193 (9.7)127 (11.5)414 (9.1) Unknown366 (0.8)24 (0.7)0 (0.0)151 (0.8)57 (1.0)0 (0.0)45 (1.3)0 (0.0)31 (1.0)27 (1.4)6 (0.5)25 (0.5) Urban resident, *n* (%)36,614 (84.1)3016 (83.8)193 (86.2)16,263 (83.5)5100 (85.3)147 (89.1)2864 (83.7)42 (79.2)2649 (89.3)1748 (88.0)911 (82.8)3681 (80.8)*HMO* health maintenance organization, *IV* intravenous, *POS* point of service, *PPO* preferred provider organization, *QD* once daily, *QM* once monthly, *Q3M* once every 3 months, *Q6M* once every 6 months, *QW* once a week, *SC* subcutaneous, *SD* standard deviation Table 2Clinical characteristics during baselineCharacteristicAll *N* = 43,543Denosumab SC Q6M *n* = 3599Alendronate QD *n* = 224Alendronate QW *n* = 19,486Ibandronate QM *n* = 5981Ibandronate IV Q3M *n* = 165Raloxifene QD *n* = 3423Risedronate QD *n* = 53Risedronate QW *n* = 2968Risedronate QM *n* = 1986Teriparatide SC QD *n* = 1100Zoledronic acid IV annually *n* = 4558CCI, mean (SD)0.6 (1.0)0.8 (1.2)0.6 (0.9)0.6 (1.0)0.5 (0.9)0.9 (1.2)0.4 (0.8)0.6 (1.0)0.5 (1.0)0.5 (0.9)0.8 (1.2)0.7 (1.1)Unique ICD-9-CM diagnoses, mean (SD)12 (7)14 (8)11 (7)11 (7)11 (7)15 (9)11 (7)13 (7)12 (7)12 (7)16 (9)14 (8)Unique osteoporosis drugs received, mean (SD)12 (9)14 (10)12 (8)11 (9)11 (9)15 (11)10 (8)14 (11)11 (9)11 (8)16 (12)14 (10)Diagnosis of osteoporosis, *n* (%)11,508 (26.4)2053 (57.0)27 (12.1)3274 (16.8)1137 (19.0)82 (49.7)714 (20.9)12 (22.6)718 (24.2)483 (24.3)764 (69.5)2244 (49.2)Diagnosis of osteopenia, *n* (%)5291 (12.2)337 (9.4)27 (12.1)2154 (11.1)794 (13.3)20 (12.1)576 (16.8)3 (5.7)438 (14.8)288 (14.5)132 (12.0)522 (11.5)Osteoporosis therapy, *n* (%)5721 (13.1)1007 (28.0)18 (8.0)1887 (9.7)773 (12.9)38 (23.0)423 (12.4)5 (9.4)444 (15.0)227 (11.4)277 (25.2)622 (13.6)Osteoporosis-related fractures, *n* (%)3388 (7.8)394 (10.9)21 (9.4)1441 (7.4)340 (5.7)9 (5.5)158 (4.6)6 (11.3)190 (6.4)120 (6.0)334 (30.4)375 (8.2)High risk for fracture, *n* (%)15,981 (36.7)1825 (50.7)79 (35.3)7191 (36.9)1741 (29.1)75 (45.5)891 (26.0)26 (49.1)937 (31.6)571 (28.8)614 (55.8)2031 (44.6)Renal insufficiency, *n* (%)1217 (2.8)196 (5.4)5 (2.2)568 (2.9)134 (2.2)4 (2.4)53 (1.5)1 (1.9)61 (2.1)50 (2.5)46 (4.2)99 (2.2)GI side effects, *n* (%)6230 (14.3)690 (19.2)34 (15.2)2235 (11.5)764 (12.8)44 (26.7)517 (15.1)5 (9.4)436 (14.7)260 (13.1)209 (19.0)1036 (22.7)*CCI* Charlson Comorbidity Index, *GI* gastrointestinal, *ICD-9-CM* International Classification of Diseases, Ninth Revision, Clinical Modification, *IV* intravenous, *QD* once daily, *QM* once monthly, *Q3M* once every 3 months, *Q6M* once every 6 months, *QW* once a week, *SC* subcutaneous, *SD* standard deviation

Twelve-month persistence and compliance {#Sec10}
---------------------------------------

Overall, 48.4 and 41.8% of patients were persistent and compliant at 12 months of follow-up, respectively (Fig. [2a](#Fig2){ref-type="fig"}). In general, patients receiving injectable therapies had higher rates of persistence and compliance (83.4 and 81.7%, respectively) compared with those receiving oral therapies (38.8 and 30.7%, respectively). Among patients receiving injectable therapies, those receiving a therapy with a Q6M dosing frequency (i.e., denosumab) had higher rates of persistence and compliance (70.5 and 71.7%, respectively) than those receiving a therapy with a daily dosing frequency (i.e., teriparatide): 63.4 and 54.4%, respectively; the sample size for the Q3M dosing (i.e., ibandronate) was too small for meaningful analyses. Rates of persistence with oral therapies ranged from 31.7 to 44.4% among individual therapies (*P* \< 0.001 across all groups). Rates of compliance with oral therapies ranged from 19.2 to 36.6% for individual therapies (*P* \< 0.001 across all groups).Fig. 2Rates of persistence and compliance with osteoporosis therapies during 12- and 24-month follow-up. Rates of persistence (*white bars*) and compliance (*black bars*) among women receiving osteoporosis therapies of interest during **a** 12-month and **b** 24-month follow-up. *IV* intravenous, *QD* once daily, *QM* once monthly, *Q3M* once every 3 months, *Q6M* once every 6 months, *QW* once a week, *SC* subcutaneous

Twenty-four-month persistence and compliance {#Sec11}
--------------------------------------------

Rates of persistence and compliance were lower at 24 than 12 months. Overall, 26.6 and 26.3% of patients were persistent and compliant at 24 months of follow-up, respectively (Fig. [2b](#Fig2){ref-type="fig"}). Among patients receiving injectable therapies, rates of persistence and compliance were 37.2 and 41.1%, respectively. Again, rates of persistence and compliance were higher among patients receiving injectable therapy with Q6M dosing (41.2 and 46.1%, respectively) compared with daily dosing (40.8 and 39.8%, respectively). Among patients receiving oral therapies, overall rates of persistence were 23.7, ranging from 19.6 to 30.6% among individual therapies, while overall rates of compliance were 22.2%, ranging from 11.3 to 28.7% among individual therapies (*P* \< 0.001 across all groups).

Adjusted odds of persistence and compliance {#Sec12}
-------------------------------------------

Multivariable logistic regression models were estimated to compare the odds of persistence and compliance with denosumab SC and other osteoporosis therapies of interest. At 12 months, patients initiating other osteoporosis therapies were significantly less likely to be persistent (OR ranging from 0.07 to 0.25, *P* \< 0.001 for all) and compliant (OR ranging from 0.09 to 0.46, *P* \< 0.001 for all) compared with those initiating denosumab SC (Table [3](#Tab3){ref-type="table"}).Table 3Propensity score weight-adjusted odds ratios from logistic regression models, persistence and compliance (60-day gap allowance) with index therapy over 12 and 24 monthsDenosumab vs therapy12-month follow-up, OR (95% CI)24-month follow-up, OR (95% CI)PersistenceCompliancePersistenceComplianceAlendronate QD0.07 (0.05, 0.11)0.09 (0.06, 0.15)0.36 (0.22, 0.59)0.17 (0.10, 0.30)Alendronate QW0.10 (0.09, 0.11)0.18 (0.16, 0.20)0.45 (0.40, 0.51)0.35 (0.31, 0.39)Ibandronate QM0.10 (0.09, 0.11)0.18 (0.16, 0.21)0.44 (0.38, 0.50)0.34 (0.30, 0.39)Ibandronate IV Q3M0.08 (0.05, 0.12)0.10 (0.06, 0.17)0.34 (0.20, 0.60)0.21 (0.11, 0.38)Raloxifene QD0.12 (0.10, 0.14)0.22 (0.19, 0.26)0.64 (0.55, 0.74)0.47 (0.41, 0.55)Risedronate QD0.12 (0.06, 0.26)0.15 (0.06, 0.35)0.39 (0.15, 1.03)\*0.15 (0.05, 0.52)Risedronate QW0.08 (0.07, 0.09)0.11 (0.09, 0.13)0.37 (0.32, 0.44)0.22 (0.18, 0.26)Risedronate QM0.09 (0.07, 0.10)0.14 (0.12, 0.17)0.37 (0.31, 0.44)0.23 (0.19, 0.28)Teriparatide SC QD0.25 (0.20, 0.30)0.46 (0.38, 0.57)0.95 (0.77, 1.16)†0.76 (0.62, 0.93)Zoledronic acid IV annuallyn/an/a0.76 (0.67, 0.86)0.76 (0.67, 0.86)Models adjusted for age, health plan type, US Census region, urban residency, patient out-of-pocket expenditure for the index therapy, and the following baseline clinical characteristics: Charlson Comorbidity Index score, number of unique medications prescribed, diagnosis of osteoporosis, osteopenia, renal insufficiency, gastrointestinal disorders, coronary heart disease, and osteoporosis-related fracture. *CI* confidence interval, *IV* intravenous, *n/a* not applicable, *OR* odds ratio, *QD* once daily, *QM* once monthly, *Q3M* once every 3 months, *QW* once a week, *SC* subcutaneous. *P* \< 0.0001 for denosumab compared with all osteoporosis therapies\**P* = 0.063; †*P* = 0.997

At 24 months, patients initiating other osteoporosis therapies were significantly less likely to be persistent compared with those initiating denosumab SC (OR ranging from 0.36 to 0.76, *P* \< 0.001), with the exception of risedronate daily and teriparatide SC (OR 0.39 and 0.95, respectively; *P* = 0.063 and *P* = 0.997, respectively; Table [3](#Tab3){ref-type="table"}). Patients initiating other osteoporosis therapies were significantly less likely to be compliant compared with those initiating denosumab SC (OR ranging from 0.15 to 0.76, *P* \< 0.001 for all; Table [3](#Tab3){ref-type="table"}).

Sensitivity analyses {#Sec13}
--------------------

ORs were also calculated using allowable gaps in the index therapy of 30 and 90 days, instead of 60 days, over the course of 24 months. Results from these analyses using the alternative allowable gap periods did not differ substantively from those obtained using a 60-day gap allowance in the definition of persistence.

Discussion {#Sec14}
==========

In this US-based analysis of women initiating a new osteoporosis therapy, persistence and compliance were higher among those treated with injectable therapies compared with oral osteoporosis therapies over both a 1- and 2-year follow-up period, with the exception of ibandronate IV, which had a very low sample size. Persistence and compliance over 24 months were higher among patients initiating denosumab SC, an injectable therapy administered Q6M, compared with those initiating other, more frequently dosed osteoporosis therapies, including oral or injectable bisphosphonates and raloxifene.

Previous studies of persistence and compliance with osteoporosis therapies are generally limited to 1 year of follow-up. Even within that time period, persistence and compliance with osteoporosis therapies are generally poor for oral osteoporosis therapies, while injectable osteoporosis therapies are generally associated with higher rates of both persistence and compliance. The 12-month results from this study are consistent with those of other published studies. One study that pooled the data of all osteoporosis therapies found rates of overall persistence and compliance to be 50 and 68%, respectively \[[@CR21]\]. Rates of persistence with denosumab SC over 1 year have ranged between 63 and 82%, while rates of compliance have ranged between 71 and 91% \[[@CR7], [@CR19], [@CR22]\]. Rates of persistence and compliance with teriparatide have been shown to be 54 and 32%, respectively, at 1 year of follow-up and 19 and 48%, respectively, at 2 years of follow-up \[[@CR17], [@CR20]\]. Because zoledronic acid is taken once a year, studies of persistence and compliance at 1 year yield predictably high rates. For oral bisphosphonates (daily, weekly, and monthly), rates of persistence ranged from 15 to 50%, while rates of compliance ranged from 39 to 43% \[[@CR6], [@CR12]--[@CR16]\]. Rates of persistence with raloxifene ranged from 14 to 34% \[[@CR12], [@CR14], [@CR15]\].

As persistence tends to decline over time, potentially leading to poorer outcomes, knowledge of a long-term view of persistence is important for developing strategies to improve persistence and, consequently, outcomes \[[@CR23]--[@CR25]\]. Poor persistence and compliance increase the risk of fractures \[[@CR16], [@CR23], [@CR26], [@CR27]\]. In a study of over 35,000 women aged 45 years and older from an administrative claims database, compliant patients had a 21% reduction in overall fracture risk, while persistent patients had a 29% reduction in overall fracture risk \[[@CR6]\]. In a meta-analysis of six studies pooling over 171,000 patients, non-compliant patients had a 46% greater risk of experiencing fracture than their compliant counterparts, with the risk of vertebral fracture higher than hip or non-vertebral fracture \[[@CR10]\]. Poor compliance has also been shown to affect BMD: among a population of nearly 250 women in a managed care plan, those receiving bisphosphonates or estrogen with MPR ≥66% had greater increases in BMD than those with MPR \<66% \[[@CR28]\]. Because the clinical benefit of osteoporosis therapies diminishes over time upon discontinuation, persistence and compliance with medications is critical in minimizing the risk of bone fractures \[[@CR4]\].

This study provides an additional contribution to the literature with regard to long-term persistence and compliance among postmenopausal women receiving one of the currently available osteoporosis therapies. Payers, practitioners, and policy makers would benefit from an understanding of long-term persistence and its effect on treatment outcomes. Additional research is needed to understand factors associated with improved persistence and compliance.

Limitations {#Sec15}
-----------

This study has certain limitations. With regard to the osteoporosis therapies included in this study, it is important to note that because zoledronic acid is an annual therapy and the follow-up period in this study was limited to 24 months, this analysis may have underestimated persistence with zoledronic acid in patients whose gap periods overlapped with the end of the follow-up period. For risedronate daily, the sample size (*n* = 53) was too low to provide reliable comparisons.

In addition, because this study was conducted using administrative claims data from a working population of patients with employer-sponsored health insurance and Medicare patients with supplemental insurance paid for by their employers, this study population may be overall younger and healthier than patients with other types of health insurance or the uninsured. Moreover, claims data were generated for reimbursement purposes and may be subject to differences in billing and reimbursement practices. It should be noted that patients restarting their index osteoporosis therapy after a gap in therapy greater than the 14-month pre-index period may have been included in the study population and considered new to their index therapy. Results from this study may not be generalizable to osteoporosis patients without commercial or private Medicare supplemental coverage. Use of denosumab (Prolia®) before January 1, 2012, was captured by either a National Drug Code or a Healthcare Common Procedure Coding System (HCPCS) code for unclassified drugs (J3490 and J3590), where the HCPCS codes may have also been used to indicate other therapies (e.g., denosumab \[Xgeva®\] for bone problems secondary to cancer).

In this retrospective, observational study of women aged at least 50 years and initiating a new osteoporosis therapy, persistence and compliance at both 1 and 2 years were generally higher for patients receiving injectable rather than oral therapies. In particular, persistence and compliance for patients receiving an injectable therapy administered Q6M (i.e., denosumab) at 2 years was higher than for those receiving a daily injectable therapy (i.e., teriparatide) and oral therapies, especially oral bisphosphonates and raloxifene.

This study did not require approval by an institutional review board because the patient data in this analysis were de-identified by an independent third party, prior to initial review by the authors, in compliance with Health Insurance Portability and Accountability Act regulations. For this type of study formal consent is not required.
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